Skip to content
Companies

Telos Biotech

Telomere-lengthening protein for cell therapy manufacturing

Raised to date

$725K

of $2.3M offered across 1 Form D filing

Still open
$1.5M
Investors
4
Last filed
Dec 12, 2025

About

Telos Biotech is a biotechnology startup that develops technologies to enhance the manufacturing of cell therapies. The company, launched by Cambrian Bio in 2022, focuses on addressing telomere shortening during cell expansion to improve the function, longevity, and robustness of therapeutic cells used to treat cancer and age-related diseases.

The company's key differentiator is its selective telomere lengthening approach, which specifically targets and extends only the shortest telomeres. This method is designed to be safer and more effective than traditional methods, resulting in more robust and durable engineered cells.

Funding

  • EquityFiled Dec 12, 2025Form D
    $725K/ $2.3M

Product

Telovance™

Biotech Platform Technology

Telovance™ is a proprietary protein complex delivered during the ex-vivo cell expansion phase of manufacturing. It works by rapidly and safely lengthening the shortest telomeres within the therapeutic cells, without the risks associated with constitutive telomerase expression.

  • Selectively targets and lengthens critically short telomeres
  • Improves cellular lifespan, function, and therapeutic outcomes
  • Designed for seamless integration into multi-step cell engineering workflows

Built for

Cell therapy developers and manufacturers, particularly those working on CAR-T and other engineered cell products.

People on file